Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL

Exclusion Criteria

• •Women who are pregnant or lactating. Patients have breeding intent in 12 months or cannot take effective contraceptive measures during the trial measures；
• •Uncontrollable active infection within four week. Prophylactic antibiotic, antiviral and antifungal treatment is permissible. Active hepatitis B or hepatitis C virus infection, as well as acquired, congenital immune deficiency diseases, including but not limited to HIV-infected persons；
• •Used of systemic anti-tumor treatment within four weeks；
• •CNS or meningeal involvement;
• •Poor hepatic and/or renal function, defined as total bilirubin, ALT, AST, Cr more than two fold of upper normal level,Ccr\< 50 mL/min unless these abnormalities were related to the lymphoma;
• •Poor bone-marrow reserve, defined as neutrophil count less than 1.5×10⁹/L or platelet count less than 75×10⁹/L, unless caused by bone marrow infiltration;
• •New York Heart Association class III or IV cardiac failure; or Ejection fraction less than 50%;or history of following disease in past 6 months: acute coronary syndrome、acute heart failure、severe ventricular arrhythmia；
• •Known sensitivity or allergy to investigational Product;
• •Major surgery within three weeks;
• •Presence of Grade III nervous toxicity within past two weeks;
• •Active and severe infectious diseases;
• •History of DVT or PE within past 12 months；
• •Any potential drug abuse, medical, psychological or social conditions which may disturb this investigation and assessment;
• •In any conditions which investigator considered ineligible for this study.